Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...

Merck receives positive EU CHMP opinion for Capvaxive for pneumococcal vaccination in adults: Rahway, New Jersey Monday, February 3, 2025, 12:00 Hrs [IST] Merck, known as MSD outs ...

VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...

The Ministry of Health (MoH) has introduced the pneumococcal conjugate vaccine (PCV) into Brunei Darussalam’s Expanded Programme on Immunisation, effective FeB 1 as part of efforts to protect infants ...

Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...

Multidrug resistance became a serious concern in the treatment of invasive pneumococcal diseases, especially in Asian countries. After PCV7 vaccination, serotype 19A has emerged as an important ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to ...

SAN CARLOS, Calif. - Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company valued at $10.78 billion, has announced the commencement of the final stage of its Phase 2 study for VAX-31, a ...

"Given the vast unmet public health needs in invasive pneumococcal disease (IPD), we’re delighted to expand this collaboration and continue our pursuit of innovative work in PCV," remarked ...